These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 34258797)

  • 41. Von Willebrand factor and thrombosis: risk factor, actor and pharmacological target.
    Lenting PJ; Denis CV; Wohner N
    Curr Vasc Pharmacol; 2013 Jul; 11(4):448-56. PubMed ID: 23905639
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Coagulation abnormalities, bleeding, thrombosis, and management of patients with acute liver failure in Australia and New Zealand.
    Warrillow S; Fisher C; Tibballs H; Bailey M; McArthur C; Lawson-Smith P; Prasad B; Anstey M; Venkatesh B; Dashwood G; Walsham J; Holt A; Wiersema U; Gattas D; Zoeller M; Garcia Alvarez M; Bellomo R
    J Gastroenterol Hepatol; 2020 May; 35(5):846-854. PubMed ID: 31689724
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hemostasis and atherosclerosis.
    Warkentin TE
    Can J Cardiol; 1995 May; 11 Suppl C():29C-34C. PubMed ID: 7750046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease.
    Lisman T; Hernandez-Gea V; Magnusson M; Roberts L; Stanworth S; Thachil J; Tripodi A
    J Thromb Haemost; 2021 Apr; 19(4):1116-1122. PubMed ID: 33792172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preserved hemostatic status in patients with non-alcoholic fatty liver disease.
    Potze W; Siddiqui MS; Boyett SL; Adelmeijer J; Daita K; Sanyal AJ; Lisman T
    J Hepatol; 2016 Nov; 65(5):980-987. PubMed ID: 27302378
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
    Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
    Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hemostasis and coagulation monitoring and management during liver transplantation.
    Dalmau A; Sabaté A; Aparicio I
    Curr Opin Organ Transplant; 2009 Jun; 14(3):286-90. PubMed ID: 19300254
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis.
    Branchford BR; Ng CJ; Neeves KB; Di Paola J
    Thromb Res; 2015 Jul; 136(1):13-9. PubMed ID: 26014643
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantitative and qualitative analysis of platelet GPIb and von Willebrand factor in liver cirrhosis.
    Beer JH; Clerici N; Baillod P; von Felten A; Schlappritzi E; Büchi L
    Thromb Haemost; 1995 Apr; 73(4):601-9. PubMed ID: 7495066
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Portal vein thrombosis and liver cirrhosis: Long-term anticoagulation is effective and safe.
    Bergère M; Erard-Poinsot D; Boillot O; Valette PJ; Guillaud O; Chambon-Augoyard C; Dumortier J
    Clin Res Hepatol Gastroenterol; 2019 Aug; 43(4):395-402. PubMed ID: 30578107
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anticoagulation in cirrhosis.
    Villa E; De Maria N
    Liver Int; 2012 Jul; 32(6):878-9. PubMed ID: 22672641
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel.
    Prasad RN; Koh SC; Viegas OA; Ratnam SS
    Clin Appl Thromb Hemost; 1999 Jan; 5(1):60-70. PubMed ID: 10725985
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rational hemostatic management in cirrhosis: from old paradigms to new clinical challenges.
    La Mura V; Bitto N; Tripodi A
    Expert Rev Hematol; 2022 Dec; 15(12):1031-1044. PubMed ID: 36342412
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High shear induces platelet dysfunction leading to enhanced thrombotic propensity and diminished hemostatic capacity.
    Chen Z; Mondal NK; Zheng S; Koenig SC; Slaughter MS; Griffith BP; Wu ZJ
    Platelets; 2019; 30(1):112-119. PubMed ID: 29182470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists.
    Tripodi A; Primignani M; Braham S; Chantarangkul V; Clerici M; Moia M; Peyvandi F
    Dig Liver Dis; 2016 Oct; 48(10):1208-13. PubMed ID: 27470055
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Platelets as Modulators of Liver Diseases.
    Lisman T; Luyendyk JP
    Semin Thromb Hemost; 2018 Mar; 44(2):114-125. PubMed ID: 28898899
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes.
    Grobler C; Maphumulo SC; Grobbelaar LM; Bredenkamp JC; Laubscher GJ; Lourens PJ; Steenkamp J; Kell DB; Pretorius E
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708334
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anticoagulation in Patients with Liver Cirrhosis: Friend or Foe?
    Protopapas AA; Savopoulos C; Skoura L; Goulis I
    Dig Dis Sci; 2023 Jun; 68(6):2237-2246. PubMed ID: 36961672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The thromboelastometric criteria of hemostasis disorders correction during liver transplantation].
    Minov AF; Dziadz'ko AM; Rummo OO
    Anesteziol Reanimatol; 2012; (2):35-41. PubMed ID: 22834286
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The relationship between ABO blood group, von Willebrand factor, and primary hemostasis.
    Ward SE; O'Sullivan JM; O'Donnell JS
    Blood; 2020 Dec; 136(25):2864-2874. PubMed ID: 32785650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.